Fezolinetant manufacturers

Filters

Filters

Filters , active

Country of origin : India

fezolinetant

Tablets 45 mg

Dossier type
US CTD
Dossier status
Under development
Country of origin
India
GMP approvals
FDA
Comments
Reference product: Veozah®
Manufacturer #15189
The company, which was founded in 1989, is involved in developing, manufacturing, and distributing a wide range of formulations for anti-infectives, cardiovascular, anti-diabetic, dermatological, and hormone treatment. The corporation has a global presence in 170 + countries, 60+ WHO-prequalified medications, and 3700+ product registrations.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

About fezolinetant

Fezolinetant manufacturers are currently limited to the originator, Astellas Pharma, which sells it as Veozah in the US and Veoza in Europe. Fezolinetant is an oral, non-hormonal neurokinin 3 (NK3) receptor antagonist. It reduces moderate to severe hot flashes and night sweats caused by menopause. Since December 2024, its US label carries a boxed warning about rare but serious liver injury. No generic is approved. Pharmaceutical companies can prepare fezolinetant dossiers for launch after patent expiry.

Fezolinetant key facts

Property

Fezolinetant

INN

Fezolinetant

Molecular formula / weight

C16H15FN6OS / 358.4 g/mol

ATC code

G02CX06

Drug class

Neurokinin 3 (NK3) receptor antagonist (non-hormonal)

Brand names

Veozah (US); Veoza (EU)

Originator

Ogeda; acquired by Astellas in 2017

Dosage form and strength

Film-coated tablets 45 mg

Dose

45 mg once daily

Indication

Moderate to severe vasomotor symptoms (hot flashes) associated with menopause

First approval

US FDA, May 2023

EU approval

December 2023

Safety update

FDA Drug Safety Communication, September 2024; boxed warning for liver injury, December 2024

Liver testing

Before starting, monthly for the first 2 months, then at months 3, 6 and 9 (US)

Competitor

Elinzanetant (Lynkuet, Bayer), a dual NK1/NK3 antagonist approved in the US in October 2025

Generic status

None approved

Fezolinetant manufacturers and licensing history

Fezolinetant was developed by Ogeda, which Astellas acquired in 2017. The FDA approved Veozah in May 2023 as the first non-hormonal NK3 antagonist for menopausal hot flashes. The EU approved it as Veoza in December 2023.

In September 2024, the FDA warned of rare but serious liver injury after a post-marketing case. In December 2024, it added a boxed warning, its strongest warning, and increased the frequency of required liver blood tests. In October 2025, Bayer's elinzanetant (Lynkuet), a related drug, was approved in the US.

No generic fezolinetant is approved. Buyers interested in future generics should confirm the API crystal form, GMP status and freedom to operate.

Fezolinetant dosage forms and dossier types

Fezolinetant is approved as 45 mg film-coated tablets.

Form

Strengths

Typical dossier

Notes

Fezolinetant tablets

45 mg

Future US ANDA; EU CTD

Reference Veozah / Veoza

Fezolinetant API

Bulk

Future DMF

Crystal form is critical

Target market

Dossier format

Key requirement

United States

Future ANDA

Patents and new chemical entity exclusivity; boxed warning labelling

European Union

Future EU CTD

Data protection and SPC expiry

Other markets

CTD

Check local patents

Fezolinetant regulatory and patent status

The FDA approved fezolinetant in May 2023, and the EU in December 2023. In December 2024, the FDA added a boxed warning for liver injury and stricter liver testing. Fezolinetant is protected by patents and new chemical entity exclusivity, and no generic is approved. Check the FDA Orange Book and national registers before planning development.

Fezolinetant mechanism of action and therapeutic use

After menopause, falling oestrogen levels overactivate KNDy neurons in the brain's temperature control centre, which triggers hot flashes. Fezolinetant blocks NK3 receptors on these neurons and restores temperature control without using hormones. It is taken once daily for moderate to severe menopausal hot flashes, with regular liver blood tests.

Fezolinetant licensing and sourcing

Fezolinetant is currently available only from Astellas. Companies interested in this molecule usually prepare future generic dossiers or API supply. Current offers and supplier contacts are listed among the fezolinetant manufacturers on Pipelinepharma.

Frequently asked questions about fezolinetant

Who manufactures fezolinetant? Astellas makes fezolinetant and sells it as Veozah in the US and Veoza in Europe.

What is fezolinetant used for? Fezolinetant is used for moderate to severe hot flashes caused by menopause.

Does fezolinetant have a safety warning? Yes. Since December 2024, the US label has a boxed warning about rare but serious liver injury, and regular liver blood tests are required.

What forms and strengths of fezolinetant are available? Fezolinetant is available as 45 mg film-coated tablets.

Is there a generic version of fezolinetant? No. No generic fezolinetant is approved.

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.